NTRK1 and sarcoma: Interestingly, there is a growing body of data to show that a number of receptor tyrosine kinase inhibitors (RTKis), many of which are currently being trialled for paediatric sarcoma management, have immunomodulatory effects on the TME through depletion or reprogramming of immunosuppressive cell subsets and enhancement of T cell infiltration.